To bleed or not to bleed. Is that the question?
Introduction to haemostasis from a pharmacodynamic perspective
Inhibitors of the initiation of coagulation
Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice
Inhibitors of propagation of coagulation: factors V and X
Direct thrombin inhibitors
New anticoagulants: how to deal with treatment failure and bleeding complications
Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation
Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy
Anti-platelet therapy: phosphodiesterase inhibitors
Anti-platelet therapy: ADP receptor antagonists
Antiplatelet therapy: thrombin receptor antagonists
Anti-platelet therapy: glycoprotein IIb-IIIa antagonists
Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?
The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene
Trousseau's syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux
On the dosing of lepirudin
Correction to lepirudin dosage in table 1 of ‘Direct Thrombin Inhibitors’
Anticoagulants, Antiplatelets and Thrombolytics, 2nd Edition
Translation Section